Analysis shows rising second primary malignancies in CLL survivors, indicating racial and ethnic disparities endure post targeted treatments.
Key Points
This research aims to evaluate the risk of second primary malignancies (SPM) among survivors of Chronic Lymphocytic Leukemia (CLL) across different treatment eras.
Data was analyzed from the SEER database covering 2000-2022.
Risk of SPM was assessed in patients diagnosed with CLL, divided by pre-target (2000-2013) and post-target treatment eras (2014-2022).
Standardized incidence ratios for SPM were calculated and stratified by race and ethnicity.
Incidence of SPM increased from pre-target (O/E=1.26) to post-target era (O/E=1.40).
Non-Hispanic Black survivors saw the highest increase in SPM risk (from O/E=1.36 to 1.67).
Hodgkin's lymphoma had the highest risk in the post-target era (O/E=6.59).
Racial and ethnic disparities in SPM rates persisted, indicating a need for targeted survivorship strategies.